Phaseline

Targets › MAP2K4

MAP2K4 (Dual specificity mitogen-activated protein kinase kinase 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. (UniProt, P45985)

Open in Phaseline: the race on MAP2K4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Xiamen UniversityDuvalisib
Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK)
PIK3CA, PIK3CB, MAP2K4Phase 2Peripheral T Cell LymphomaDec 2026

Conditions

Peripheral T Cell Lymphoma (1)

Modalities

small molecule (1)

Companies

The First Affiliated Hospital of Xiamen University (1)

Related targets

PIK3CA (1) PIK3CB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.